HYRIMOZ

This brand name is authorized in Albania, Australia, Austria, Brazil, Croatia, Cyprus, Ecuador, Estonia, Finland, France, Germany, Hong Kong SAR China, Ireland, Israel, Lithuania, Netherlands, New Zealand, Poland, Romania, Spain, Turkey, UK.

Active ingredients

The drug HYRIMOZ contains one active pharmaceutical ingredient (API):

1	Adalimumab UNII FYS6T7F842 - ADALIMUMAB
	Adalimumab binds specifically to TNF and neutralizes the biological function of TNF by blocking its interaction with the p55 and p75 cell surface TNF receptors. Adalimumab also modulates biological responses that are induced or regulated by TNF, including changes in the levels of adhesion molecules responsible for leukocyte migration (ELAM-1, VCAM-1, and ICAM-1 with an IC50 of 0.1-0.2 nM).
	Read more about Adalimumab

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L04AB04	Adalimumab	L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AB Tumor necrosis factor alpha (TNF-α) inhibitors
Discover more medicines within L04AB04

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AL	Fondi i Sigurimit të Detyrueshëm të Kujdesit Shëndetësor	664/237, 664/237a
AU	Pharmaceutical Benefits Scheme	10399H, 10400J, 10412B, 10413C, 10419J, 10420K, 10944B, 10955N, 10960W, 10961X, 12325Q, 12326R, 12327T, 12328W, 12329X, 12330Y, 12331B, 12333D, 12334E, 12348X, 12352D, 12353E, 12355G, 12356H, 12365T, 12366W, 12367X, 12368Y, 12369B, 12370C, 12384T, 12385W, 12386X, 12387Y, 12388B, 12401Q, 12402R, 12403T, 12415K, 12416L, 12420Q, 12434K, 12437N, 12438P, 5281Y, 5282B, 5283C, 5284D, 8737W, 8741C, 8963R, 8964T, 8965W, 8966X, 9033K, 9034L, 9077R, 9078T, 9099X, 9100Y, 9101B, 9102C, 9103D, 9104E, 9188N, 9189P, 9190Q, 9191R, 9425C, 9426D, 9427E, 9428F, 9662M, 9663N, 9679K, 9680L
BR	Câmara de Regulação do Mercado de Medicamentos	511520070072107, 511520070072207
DE	Bundesinstitut für Arzneimittel und Medizinprodukte	13974778, 13974784, 13974790, 13974809, 15300765, 15300771, 15317033, 15317062, 15317079, 15317085, 15530086, 15530092, 15530100, 15530117, 15563105, 15563111, 15607452, 15607535, 15863020, 15863037, 15863043, 15863066, 15870126, 15870132, 15870149, 15870161, 16002679, 16002691, 16009948, 16009954, 16009960, 16009977, 16018255, 16018261, 16018278, 16018284, 16018462, 16018479, 16018485, 16018491, 16388779, 16388785, 16388791, 16388816, 16759448, 16759454, 16759460, 16759477, 16794686, 16958001, 16958018, 17294721, 17294738, 17312560, 17906986, 17921307
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	197-MBE-0521
EE	Ravimiamet	1777293, 1777305, 1777316, 1777327, 1777338, 1777349, 1816398
ES	Centro de información online de medicamentos de la AEMPS	1181286001, 1181286004
FI	Lääkealan turvallisuus- ja kehittämiskeskus	371157, 542236, 592241
FR	Base de données publique des médicaments	63795537, 66112231
GB	Medicines & Healthcare Products Regulatory Agency	362344, 362346
HK	Department of Health Drug Office	67013, 67014
IL	מִשְׂרַד הַבְּרִיאוּת	8809, 8810
LT	Valstybinė vaistų kontrolės tarnyba	1086031, 1086032, 1086033, 1086034, 1086035, 1086036, 1089891
NL	Z-Index G-Standaard, PRK	106348, 167207, 84492
NZ	Medicines and Medical Devices Safety Authority	20527, 20528
PL	Rejestru Produktów Leczniczych	100408933, 100452941
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W64999001
TR	İlaç ve Tıbbi Cihaz Kurumu	8681428951499, 8681428951505